PeptiDream (4587) Q4 2025 earnings summary

Executive summary

• Transitioned from a discovery-focused start-up to a global pharmaceutical company with a robust pipeline in macrocyclic peptide therapeutics and radiopharmaceuticals, ending FY2025 with 13 clinical programs, nearly doubling from the previous year.

• Maintained profitability in radiopharmaceuticals for the fourth consecutive year, despite missing initial revenue forecasts in drug discovery and reporting a net loss of ¥3.7 billion for FY2025.

• Management expanded with new EVP, SVP, and VP roles, and major investments in R&D and manufacturing facilities were initiated to support future growth.

• No dividends were paid or forecasted, with management prioritizing R&D investment and internal reserves over shareholder returns.

Financial highlights

• FY2025 revenue was ¥18.5 billion, significantly below the initial forecast of ¥49 billion, mainly due to delayed out-licensing and milestone deals; EBITDA was negative at ¥2.8 billion, and net loss was ¥3.7 billion.

• Radiopharmaceuticals contributed ¥15.7 billion in revenue, while drug discovery and development brought in ¥2.8 billion.

• Cash and cash equivalents decreased to ¥28.7 billion, down ¥19.4 billion from the prior year.

• Equity ratio improved to 67% from 61% in FY2024, maintaining a net cash positive position.

• FY2026 revenue forecast is ¥32 billion plus potential upside from out-licensing deals; R&D expenses expected to rise to ¥6.5 billion.

Outlook and guidance

• FY2026 revenue forecast is ¥32 billion (+72.8% YoY), with core operating profit expected at ¥4.6 billion or higher, and 6–12 new clinical programs anticipated to enter development, targeting 19–25 programs by year-end.

• Conservative revenue guidance separates high-probability projects from potential large lump-sum deals.

• Long-term goal to reach ¥100 billion in annual revenue, driven by core therapeutic areas and expanding clinical pipeline.